Abstract：
BACKGROUND: Despite the greater sensitivity and specificity of disease-specific patient-reported outcome measures (PROM) to detect clinical change, only recently have such instruments been developed for pulmonary hypertension (PH), specifically pulmonary arterial hypertension (PAH) and chronic thromboembolic disease (CTEPH). Although these valuable tools are now being incorporated into clinical studies of PH, they have not yet reached widespread integration into routine clinical care.
OBJECTIVE: In this systematic review, the authors assess the psychometric properties of PROM developed for PH, compare PROM with other clinical outcomes in PH, and address the utility of PROM in clinical care.
METHODS: The authors performed a systematic search of papers published between January 1, 2006, and October 1, 2022, using the MEDLINE database to identify PROM developed and validated for PH. The identified PROM were found to have been developed only in groups with PAH and CTEPH. The authors evaluated the identified instruments according to established psychometric criteria. An additional search was performed to identify randomized controlled trials (RCTs) utilizing these PROM for comparison with clinical outcomes.
RESULTS: From 527 papers retrieved, a total of 35 PROM were identified. Of these, 5 disease-specific instruments were included in the final analysis. While both CAMPHOR (Cambridge Pulmonary Hypertension Outcome Review) and emPHasis-10 performed well in patients with PAH and CTEPH with regard to their psychometric properties, emPHasis-10 demonstrated superior feasibility for use in clinical practice due to its concise format. The Pulmonary Arterial Hypertension-Symptoms and Impacts Questionnaire performed well in the authors\' analysis, though additional data is needed regarding interpretability and feasibility.
CONCLUSIONS: EmPHasis-10 demonstrated strong psychometric properties and the greatest feasibility for clinical use. Further study assessing the integration of PROM into routine clinical care for PH is needed.
OBJECTIVE: In this systematic review, the authors assess the psychometric properties of PROM developed for PH, compare PROM with other clinical outcomes in PH, and address the utility of PROM in clinical care.
METHODS: The authors performed a systematic search of papers published between January 1, 2006, and October 1, 2022, using the MEDLINE database to identify PROM developed and validated for PH. The identified PROM were found to have been developed only in groups with PAH and CTEPH. The authors evaluated the identified instruments according to established psychometric criteria. An additional search was performed to identify randomized controlled trials (RCTs) utilizing these PROM for comparison with clinical outcomes.
RESULTS: From 527 papers retrieved, a total of 35 PROM were identified. Of these, 5 disease-specific instruments were included in the final analysis. While both CAMPHOR (Cambridge Pulmonary Hypertension Outcome Review) and emPHasis-10 performed well in patients with PAH and CTEPH with regard to their psychometric properties, emPHasis-10 demonstrated superior feasibility for use in clinical practice due to its concise format. The Pulmonary Arterial Hypertension-Symptoms and Impacts Questionnaire performed well in the authors\' analysis, though additional data is needed regarding interpretability and feasibility.
CONCLUSIONS: EmPHasis-10 demonstrated strong psychometric properties and the greatest feasibility for clinical use. Further study assessing the integration of PROM into routine clinical care for PH is needed.
摘要：
背景：尽管疾病特异性患者报告结果指标（PROM）检测临床变化的敏感性和特异性更高，直到最近才开发出用于肺动脉高压（PH）的仪器，特别是肺动脉高压（PAH）和慢性血栓栓塞性疾病（CTEPH）。虽然这些有价值的工具现在被纳入到PH的临床研究中，他们尚未广泛整合到常规临床护理中。
目的：在本系统综述中，我们评估了为PH开发的PROM的心理测量特性，将PROM与PH的其他临床结果进行比较，并解决了PROM在临床护理中的实用性。
方法：作者使用MEDLINE数据库对2006年1月1日至2022年10月1日之间发表的论文进行了系统搜索，以确定针对PH开发和验证的PROM。发现鉴定的PROM仅在PAH和CTEPH组中发展。作者根据既定的心理测量标准评估了确定的仪器。进行了额外的搜索，以确定使用这些PROM的随机对照试验（RCT）与临床结果进行比较。
结果：从检索到的527篇论文中，总共确认了35例PROM。其中,最终分析中包括5种疾病特异性仪器。虽然剑桥肺动脉高压结果审查（CAMPHOR）和XXX（emPHasis-10）在PAH和CTEPH患者的心理测量特性方面表现良好，emPHasis-10由于其简洁的格式而证明了在临床实践中使用的优越可行性。肺动脉高压-症状和影响问卷在作者分析中表现良好，尽管需要关于可解释性和可行性的额外数据。
结论：Emphasis-10表现出强大的心理测量特性和最大的临床应用可行性。需要进一步研究评估将PROM整合到PH的常规临床护理中。
目的：在本系统综述中，我们评估了为PH开发的PROM的心理测量特性，将PROM与PH的其他临床结果进行比较，并解决了PROM在临床护理中的实用性。
方法：作者使用MEDLINE数据库对2006年1月1日至2022年10月1日之间发表的论文进行了系统搜索，以确定针对PH开发和验证的PROM。发现鉴定的PROM仅在PAH和CTEPH组中发展。作者根据既定的心理测量标准评估了确定的仪器。进行了额外的搜索，以确定使用这些PROM的随机对照试验（RCT）与临床结果进行比较。
结果：从检索到的527篇论文中，总共确认了35例PROM。其中,最终分析中包括5种疾病特异性仪器。虽然剑桥肺动脉高压结果审查（CAMPHOR）和XXX（emPHasis-10）在PAH和CTEPH患者的心理测量特性方面表现良好，emPHasis-10由于其简洁的格式而证明了在临床实践中使用的优越可行性。肺动脉高压-症状和影响问卷在作者分析中表现良好，尽管需要关于可解释性和可行性的额外数据。
结论：Emphasis-10表现出强大的心理测量特性和最大的临床应用可行性。需要进一步研究评估将PROM整合到PH的常规临床护理中。
